A phase 3, double-blind, parallel-group study to evaluate the efficacy and safety of tezacaftor in combination with ivacaftor in participants 6 through 11 years of age with cystic fibrosis homozygous for F508del or heterozygous for the F508del-CFTR mutation and a residual function mutation
| Autor: | Davies, Jane C., Sermet-Gaudelus, Isabelle, Naehrlich, Lutz, Harris, R. Scott, Campbell, Daniel, Ahluwalia, Neil, Short, Christopher, Haseltine, Eric, Panorchan, Paul, Saunders, Clare, Owen, Caroline A., Wainwright, Claire E. |
|---|---|
| Zdroj: | In Journal of Cystic Fibrosis January 2021 20(1):68-77 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect